(Q33394281)

English

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study (English)

1 reference

Europe PubMed Central

26 July 2017

multicenter clinical trial

0 references

18

object named as

Brianna Harris

1 reference

Europe PubMed Central

26 July 2017

object named as

Patricia Maiso

13

0 references

object named as

Aldo Roccaro

14

0 references

Paul G. Richardson

23

object named as

Paul G Richardson

1 reference

Europe PubMed Central

26 July 2017

Kenneth C. Anderson

22

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

26 July 2017

Nikhil V Munshi

4

object named as

Nikhil C Munshi

1 reference

Europe PubMed Central

26 July 2017

1

object named as

Irene M Ghobrial

1 reference

Europe PubMed Central

26 July 2017

Jacob P Laubach

11

object named as

Jacob Laubach

1 reference

Europe PubMed Central

26 July 2017

9

object named as

Stacey Chuma

1 reference

Europe PubMed Central

26 July 2017

21

object named as

Scott Rodig

1 reference

Europe PubMed Central

26 July 2017

Robert Schlossman

7

object named as

Robert Schlossman

1 reference

Europe PubMed Central

26 July 2017

10

object named as

Janet Kunsman

1 reference

Europe PubMed Central

26 July 2017

20

object named as

Amy Sam

1 reference

Europe PubMed Central

26 July 2017

3

object named as

Ravi Vij

1 reference

Europe PubMed Central

26 July 2017

5

object named as

Ranjit Banwait

1 reference

Europe PubMed Central

26 July 2017

Andrzej Jakubowiak

12

object named as

Andrzej J Jakubowiak

1 reference

Europe PubMed Central

26 July 2017

author name string

Edie Weller

2

1 reference

Europe PubMed Central

26 July 2017

Meghan Bagshaw

6

1 reference

Europe PubMed Central

26 July 2017

Renee Leduc

8

1 reference

Europe PubMed Central

26 July 2017

Philippe Armand

15

1 reference

Europe PubMed Central

26 July 2017

Akari Dollard

16

1 reference

Europe PubMed Central

26 July 2017

Diane Warren

17

1 reference

Europe PubMed Central

26 July 2017

Tiffany Poon

19

1 reference

Europe PubMed Central

26 July 2017

publication date

21 February 2011

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

12

1 reference

Europe PubMed Central

26 July 2017

3

1 reference

Europe PubMed Central

26 July 2017

263-272

1 reference

Europe PubMed Central

26 July 2017

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

AKT and cancer--is it all mTOR?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Why is PTEN an important tumor suppressor?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

PI3K/Akt signalling pathway and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular targeting: PI3 kinase pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

TOR complex 2: a signaling pathway of its own.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970028-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70028-6

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33394281&oldid=1903861810"